Inhibrx Biosciences, Inc.
INBX
$14.00
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1.69B | 1.64B | 1.63B | -251.02M | -241.36M |
| Total Depreciation and Amortization | 2.29M | 1.89M | 1.44M | 1.26M | 1.19M |
| Total Amortization of Deferred Charges | 2.07M | 3.31M | 4.55M | 4.90M | 4.90M |
| Total Other Non-Cash Items | -1.94B | -1.93B | -1.93B | 27.00M | 26.61M |
| Change in Net Operating Assets | 52.05M | 80.40M | 60.07M | 11.18M | 15.35M |
| Cash from Operations | -194.41M | -207.51M | -231.47M | -206.68M | -193.31M |
| Capital Expenditure | -2.60M | -6.02M | -6.59M | -5.69M | -4.59M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2.60M | -6.02M | -6.59M | -5.69M | -4.59M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 71.68M | 72.76M | 272.78M | 202.32M | 202.32M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -225.00K | -355.00K | 14.12M | -355.00K |
| Cash from Financing | 71.68M | 72.54M | 272.43M | 216.43M | 201.96M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -125.33M | -141.00M | 34.37M | 4.06M | 4.06M |
